Topics:
Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • Hepatocellular Carcinoma • Journal Club ft. NEJM publications
When would you continue atezolizumab/bevacizumab beyond progression in advanced HCC?
What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?
Answer from: Medical Oncologist at Academic Institution
The key parameters I use when considering treatment beyond progression for a patient on atezolizumab bevacizumab are clinical symptoms as compared to baseline, performance status as compared to baseline, and underlying hepatic function as compared to baseline. If there is worsening in any of these a...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There are many effective drugs now in HCC. If there is true progression, I would change therapy. What is true progression? I think, a confirmed new lesion and/ or significant growth of the current disease. A few mm seen on a scan sometimes is read by radiology as PD but if the lesion is 8 mm, it's n...